Sanofi Ends Cancer and Coronary Drug Trials

Two phase 3 trials -- one for the cancer-fighting drug Iniparib and the other for Otamixaban, a therapy designed for use in treating coronary disease -- have been terminated due to a lack of results, Sanofi (NYSE: SNY  ) announced today.

In the Iniparib study, newly diagnosed cell lung patients were treated with the drug in conjunction with chemotherapy. According to Sanofi, "There were no clinically meaningful differences in the main safety parameters," compared to patients who received chemotherapy alone. Ending development of Iniparib will result in a $235 million non-cash charge recognized on Sanofi's June 30, 2013 consolidated balance sheet.

The results for the anticoagulant Otamixaban were also unsuccessful and the drug did not "meet its primary endpoint of superiority over current therapy," according to Sanofi. Following the study, it was determined that the investigational program for Otamixaban will also be discontinued.

link


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2468927, ~/Articles/ArticleHandler.aspx, 8/22/2014 3:40:03 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement